Emerging Vaccines | Disease Landscape & Forecast | G7 | 2024
Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their lives to prevent infections and diseases associated with long-term chronic disorders. Although vaccination guidelines may offer strong recommendations for certain vaccines, other vaccines are administered at the discretion of the prescribing physician and the patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccine market remain attractive for the development of new prophylactic options. This content includes coverage of current and emerging vaccines for key infectious diseases such as HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19. We also assess the impact of the COVID-19 pandemic on the vaccines market.
Questions answered
- What are the sizes of the populations eligible for key vaccination programs in the G7?
- What are the key drivers of brand preference in a given vaccine market?
- How will the current vaccine pipeline fulfill areas of unmet need in this market?
- How will key current and emerging vaccines perform commercially?
- How has the COVID-19 pandemic impacted the use of current vaccines?
Geographies: United States, EU5, Japan
Primary research: 16 country-specific interviews with thought-leading infectious disease specialists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Vaccine-eligible and vaccinated events of emerging vaccines by country, segmented by key infectious diseases (HPV, HZ, meningococcus, pneumococcus, seasonal influenza, HBV, RSV, COVID-19).
Forecast: 10-year, annualized, vaccine-level sales and patient share of key vaccines through 2033, segmented by vaccines, geography, and key indications.
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
